Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 8/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | F2R | P25116 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27626212 | 0.88 | GAA (0.33) | GAADPP4JAK2DPP7 | |
| SCHEMBL15808559 | 0.83 | GAA (0.33) | GAAKDM4EALDH1A1DPP4F2R | |
| SCHEMBL932224 | 0.80 | KDM4E (0.35) | GAAKDM4EALDH1A1DPP4F2R | |
| SCHEMBL4629631 | 0.80 | KDM1A (0.33) | GAAALDH1A1KDM1AMAOAMAOB | |
| SCHEMBL14655947 | 0.79 | KCNH2 (0.34) | GAAKDM4EALDH1A1DPP4DPP8 | |
| SCHEMBL2707285 | 0.78 | ALDH1A1 (0.34) | KDM4EALDH1A1DPP4F2RJAK2 | |
| SCHEMBL6107767 | 0.78 | EPHX2 (0.43) | KDM4EDPP4 | |
| SCHEMBL15808560 | 0.78 | CPN1 (0.46) | GAAALDH1A1DPP4DPP8DPP9 | |
| SCHEMBL22647255 | 0.77 | — | — | |
| SCHEMBL18855612 | 0.75 | ALDH1A1 (0.54) | ALDH1A1DPP4F2RHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787540-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES, ASTHMA, OSTEOPOROSIS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-09-07 | — | — | US | claimed |
| EP-1322613-A1 | SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-07-02 | — | — | EP | claimed |
| US-20020137932-A1 | Novel compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | claimed |
| WO-2002020485-A1 | SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | claimed |
| EP-2507229-B1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2016-10-05 | — | — | EP | disclosed |
| CN-103153993-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (BS) | 2016-06-01 | — | — | CN | disclosed |
| EP-2576546-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE BAHAMAS LTD (BS) | 2015-07-22 | — | — | EP | disclosed |
| US-9073855-B2 | BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9045420-B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9034875-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9029404-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2507211-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2014-06-18 | — | — | EP | disclosed |
| US-6720319-B2 | ((1-(4-CYANO-1-(2-MORPHOLIN-4-YL-ETHYL)-PIPERIDIN-4 -YLCARBAMOYL)- 2-CYCLOHEXYL-ETHYLAMINO) -MORPHOLIN-4-YL-METHYLENE)- CARBAMIC ACID ISOBUTYL ESTER; CATHEPSINS S, K, F, L AND B; AUTOIMMUNE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20040006078-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030232826-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACIUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030216383-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-11-20 | — | — | US | disclosed |
| EP-1322613-A1 | SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6525052-B2 | Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020137932-A1 | Novel compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| WO-2002020485-A1 | SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232826-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | GAA 293/4885KDM4E 3097/4885ALDH1A1 3667/4885 |
| US-20040006078-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | GAA 293/4885KDM4E 3097/4885ALDH1A1 3667/4885 |
| US-20030216383-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | GAA 293/4885KDM4E 3097/4885ALDH1A1 3667/4885 |
| US-20020137932-A1 | Novel compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | GAA 361/4885KDM4E 3092/4885ALDH1A1 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.